Filing Details

Accession Number:
0001209191-23-006422
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-02-02 19:02:35
Reporting Period:
2023-01-31
Accepted Time:
2023-02-02 19:02:35
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1438533 Travere Therapeutics Inc. TVTX Pharmaceutical Preparations (2834) 262383102
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1943192 R. Christopher Cline C/O Travere Therapeutics, Inc.
3611 Valley Centre Drive, Ste 300
San Diego CA 92130
Chief Financial Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2023-01-31 20,250 $0.00 53,121 No 4 A Direct
Common Stock Disposition 2023-02-01 1,588 $21.75 51,533 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 A Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Employee stock option (right to buy) Acquisiton 2023-01-31 54,500 $0.00 54,500 $22.40
Common Stock Performance-based restricted stock units Acquisiton 2023-01-31 6,750 $0.00 6,750 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
54,500 2033-01-30 No 4 A Direct
6,750 No 4 A Direct
Footnotes
  1. Each restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer.
  2. Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.
  3. One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter.
  4. This grant will vest upon the achievement of a specified clinical/regulatory milestone, provided, however, if the vesting event occurs before the date that is 12 months after the date of grant, then the award will instead vest on the date that is 12 months after the date of grant, and provided further that the Performance RSU will expire on January 31, 2027 if the specified performance based milestone is not achieved by such date.